Predicine, a molecular information company based in Silicon Valley, has developed a portfolio of regulated liquid biopsy genomic products to help advance the science of precision medicine in cancer. Its patented GeneRADAR is a RNA + DNA-based liquid biopsy test for early cancer detection, disease monitoring and minimal residual disease assessment. It offers a 600 gene-panel to facilitate biomarker-driven patient enrollment in clinical trials. With its vast data sets and advanced analytics, Predicine partners with 30+ biopharmas to support their clinical trials in US, EU, Australia and China. It operates in US and China.